Patient satisfaction and preference with the EVRA transdermal contraceptive patch compared to the previous contraceptive method

Patient satisfaction and preference with the EVRA transdermal

contraceptive patch compared to the previous contraceptive method

F. Weisberg (1), C. Bouchard (2), M. Moreau (3), M. Audet (4), S. Mawdsley

(5), J. Zecevic (6), G.L.A. Horbay (6), D. Dattani (7)

Private practice, Toronto, ON, Canada (1); Centre Médical Santé Femme,

Quebec, QC, Canada (2); Private practice, Montreal, QC, Canada (3); Centre

Medical Halles de Ste-Foy , Sainte-Foy, QC, Canada (4); Dartmouth Professional

Centre, Dartmouth, NS, Canada (5); Janssen-Ortho Inc, Toronto, ON, Canada (6);

Acadia Medical Centre, Saskatoon, SK, Canada (7)

Objectives: An open-label, multicentre phase IV study evaluated

preference and satisfaction for the EVRA transdermal contraceptive patch, after

9 cycles compared to previously used contraceptive methods.

Design and Methods: To assess preference and satisfaction, 392 healthy

women were enrolled. EVRA delivers 150mcg norelgestromin/ 20mcg ethinyl

estradiol daily. Treatment cycles required 3 consecutive 7-day patch

applications, followed by 1 patchfree week. At final visit patients

ratedsatisfaction (Very satisfied/ some what satisfied/ neither satisfied/

dissatisfied/dissatisfied/ very dissatisfied) and preference for EVRA compared

to their previous method. Pearl indices were calculated. Safety and compliance

were also assessed.

Results: 302 patients completed >/=6 cycles. Baseline satisfaction

with previous contraceptive method was 81% (42% very satisfied, 39% somewhat

satisfied); 89% used oral contraceptives. After 9 cycles (n=279), 91% were

satisfied with EVRA (70% very satisfied, 21% somewhat satisfied), and 75%

preferred EVRA to the previous contraceptive (43% strongly preferred, 32%

preferred); 9% had no preference; 16% preferred their previous method (14%

preferred, 2% strongly preferred). Preference for EVRA was not different across

age groups (18–20y 76%; 21–24y 77%; 25–34y 67%; 35–45y 74%). Of parous

patients, 82% preferred EVRA, 9.5% preferred their previous method. Of

nulliparous patients, 69% preferred EVRA, 21% preferred previous method. Overall

and method-failure Pearl Indices were 0.934 and 0.481. The most common adverse

events were application site reactions, breast discomfort, headache, and nausea.

Across cycles, 88% of subjects had perfect compliance; this was not influenced

markedly by age (18–20y 89%; 21–24y 88%; 25–34y 86%; 35–45y 93%).

Conclusions: Preference and satisfaction for EVRA was high compared to

the previously used contraceptive method and was not influenced by age or parity.

Compliance was good throughout for all age groups.

Scroll to Top